

Volume 64

Number 2

AUGUST 2001

# Contraception

*An International Journal*

Daniel R. Mishell, Jr., M.D.  
Editor

Official Journal of the Association  
of Reproductive Health Professionals

<http://www.elsevier.com/locate/contraception>

HEALTH SCIENCES LIBRARY  
UNIVERSITY OF WISCONSIN

NOV 09 2001

1305 Linden Drive  
Madison, WI 53706

Elsevier

Warner Chilcott v. Lupin Ltd., et al.,  
C.A. 11-05048 (JAP) (TJB)  
Warner Chilcott v. Watson Labs.,  
C.A. 12-2928 (JAP) (TJB)

**DOCKET  
ALARM**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).

# Contraception

An International Journal

Contraception (ISSN 0010-7824) is published monthly, two volumes per year, by Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010, USA. Periodicals postage paid at New York, NY and additional mailing offices. US Postmaster: Send address changes to Contraception, Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010, USA.

**Publisher and Advertising Offices:** Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010, USA. Telephone: (212) 989-5800; Fax: (212) 633-3990.

**Rates:** For customers in Europe, The CIS, and Japan: Institutional: NLG 1231.00 (euro 558.60); JPY 79,000.00; Personal: NLG 44 (euro 203.75); JPY 28,200.00; Student/Resident: NLG 197.00. For customers in all other countries: Institutional: US \$625.00; Personal: US \$228.00; Student/Resident: US \$100.00. Prices include postage and are subject to change without notice. Any inquiry relating to subscriptions should be sent to the Regional Sales office nearest you. **New York:** Elsevier Science, Customer Support Department, PO Box 945, New York, NY 10010, USA [Tel: (+1) 212-633-3730/1-888-4ES-INFO. Fax: (+1) 212-633-3680. E-mail: usinfo@elsevier.com].

**Tokyo:** Elsevier Science Customer Support Department, 9-15 Higashi-Azabu 1-chome, Minato-ku, Tokyo 106, Japan [Tel: (+3) 5561-5033. Fax: (+3) 5561-5047. E-mail: ky04035@nlitsyerve.or.jp]. **Singapore:** Elsevier Science (Singapore) Pte Ltd, No. 1 Temasek Avenue, 17-01 Millenia Tower, Singapore 039192 [Tel: (+65) 434-3727. Fax: (+65) 337-2230. E-mail: asiainfo@elsevier.com.sg]. **Rio de Janeiro:** Elsevier Science, Rua Sete de Setembro 111/16 Andar, 20050-002 Centro, Rio de Janeiro, RJ, Brazil. [Tel: (+55) 21-509-5340. Fax: (+55) 21-507-1991. E-mail: elsevier@campus.com.br] (Note: customers in Latin America should contact the New York office listed above). **Amsterdam:** Elsevier Science Customer Service Department, PO Box 211, 1001 AE Amsterdam, The Netherlands. [Tel: (+31) 20-485-3757. Fax: (+31) 20-485-3432. E-mail: nlinfo@elsevier.nl].

Claims for missing issues can be honored only up to three months for domestic addresses, six months for foreign addresses. Duplicate copies will not be sent to replace ones undelivered through failure to notify Elsevier of change of address.

**For advertising orders and inquiries: North and South America:** Hank Blaney, Elsevier Science, Inc., 655 Avenue of the Americas, New York, NY 10010. Tel.: (212) 633-3648, Fax: (212) 633-3820, e-mail: h.blaney@elsevier.com. **International:** Advertising Department, Elsevier Science, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England. Tel.: +44-(0)1865-843-565, Fax: +44-(0)1865-843-976, e-mail: media@elsevier.co.uk. **Japan:** Advertising Department, Elsevier Science Japan, Tel.: +81-3-5561-5033, Fax: +81-3-5561-5047.

**Commercial reprint inquiries** should be addressed to Inez Herrero, Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010. Tel: (212) 633-3874; Fax: (212) 633-3820; E-mail: iherrero@elsevier.com

© 2001 by Elsevier Science Inc. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by Elsevier Science Inc., and the following terms and conditions apply to their use:

**Photocopying:** Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Permissions may be sought directly from Elsevier Science Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865-843-830, fax: (+44) 1865-853-333, e-mail: permissions@elsevier.co.uk. You may also contact Rights & Permissions directly through Elsevier's home page (<http://www.elsevier.nl>), selecting first 'Customer Support', then 'General Information', then 'Permissions Query Form.'

In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 750-8400, fax: (978) 750-4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 171-436-5931; fax: (+44) 171-436-3986. Other countries may have a local reprographic rights agency for payments.

**Derivative Works:** Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution.

Permission of the publisher is required for all other derivative works, including compilations and translations.

**Electronic Storage or Usage:** Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated.

Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Address permissions requests to: Elsevier Science Rights & Permissions Department, at the mail, fax and e-mail addresses noted above.

**Notice:** No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

 This paper meets the requirements of ANSI Standard Z39.48-1992 (Permanence of Paper).

## ORIGINAL RESEARCH ARTICLES

- 77 Case-controlled study on relevant factors of adolescent sexual coercion in China**  
Cheng Yimin, Kang Baohua, Wang Tieyan, Han Xuejun, Shen Huan, Lu Yuren, Han Lihui, Cui Ying, Liu Hua, Yu Wenhuan, Wu Mei, Wang Jinying, Zhang Yongmei, and Yu Qiusheng
- 81 Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion**  
Eric A. Schaff, Stephen L. Fielding, and Carolyn Westhoff
- 87 Mifepristone followed on the same day by vaginal misoprostol for early abortion**  
Helen C. Pymar, Mitchell D. Creinin, and Jill L. Schwartz
- 93 Immune response of male baboons to testis-specific LDH-C<sub>4</sub>**  
Erwin Goldberg, John L. VandeBerg, Mary C. Mahony, and Gustavo F. Doncel
- 99 Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 µg ethinyl estradiol and 75 µg gestodene**  
J. Endrikat, M. Cronin, C. Gerlinger, A. Ruebig, W. Schmidt, and B. Düsterberg
- 107 Emergency contraception with Multiload Cu-375 SL IUD: a multicenter clinical trial**  
Zhou Liying and Xiao Bilian
- REVIEW ARTICLE**
- 113 Gel-microemulsions as vaginal spermicides and intravaginal drug delivery vehicles**  
Osmond J. D'Cruz and Fatih M. Uckun
- ORIGINAL RESEARCH ARTICLE (CONTINUED)**
- 125 Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis**  
Sean Hennessy, Jesse A. Berlin, Judith L. Kinman, David J. Margolis, Sue M. Marcus, and Brian L. Strom
- 135 Subject Index Volume 63**

Contraception is indexed in *Bibliography of Reproduction*, *Biological Abstracts*, *Chemical Abstracts*, *Elsevier BIOBASE/Current Awareness in Biological Sciences*, *Current Contents*, *EMBASE/Excerpta Medica*, *Index Medicus*, *International Pharmaceutical Abstracts*, *Derwent Drug File*, and *Population Index*. Articles are abstracted monthly in *Core Journals in Obstetrics and Gynecology*.

## Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 $\mu\text{g}$ ethinyl estradiol and 75 $\mu\text{g}$ gestodene

J. Endrikat<sup>a,\*</sup>, M. Cronin<sup>a</sup>, C. Gerlinger<sup>a</sup>, A. Ruebig<sup>a</sup>, W. Schmidt<sup>b</sup>, B. Düsterberg<sup>a</sup>

<sup>a</sup>Schering AG, Müllerstr. 178, D-13342 Berlin, Germany

<sup>b</sup>Universitätskliniken des Saarlandes, Frauenklinik und Poliklinik, D-66421 Homburg/Saar, Germany

Received 17 April 2001; accepted 29 May 2001

### Abstract

This prospective, double-blind, randomized study was conducted to compare the contraceptive reliability, cycle control, and tolerability of a 23-day versus a 21-day oral contraceptive regimen containing 20  $\mu\text{g}$  ethinyl estradiol and 75  $\mu\text{g}$  gestodene. Participants took trial medication daily for 28 days, either 23 tablets with active substances plus 5 placebo tablets or 21 tablets with active substances plus 7 placebo tablets. Contraceptive efficacy, cycle control, and tolerability were evaluated over a period of seven cycles. Efficacy data gathered from 4,878 treatment cycles (23-day regimen: 2,362 cycles; 21-day regimen: 2,516 cycles) were obtained from 703 participants (23-day regimen,  $n = 342$ ; 21-day regimen,  $n = 361$ ).

Both preparations proved to be effective contraceptives and provided good cycle control. One pregnancy because of method failure was recorded in each treatment group. This resulted in a study Pearl Index of 0.5 for each treatment. For the 23-day regimen, 36.0% of participants reported at least one intracyclic bleeding episode during Cycles 2–4 (primary target) compared to 37.1% in the 21-day regimen. In the 23-day regimen group, intracyclic bleeding episodes were reported by 42.4% of the participants in Cycle 1 but only in 14% in Cycle 7 and in the 21-day regimen group by 44.6% in Cycle 1 and only 17.3% in Cycle 7. Overall, intracyclic bleeding was reported in 21.9% of the 23-day regimen cycles and in 22.7% of the 21-day regimen cycles.

A greater number of 23-day regimen participants had shorter withdrawal bleeding periods than with the 21-day regimen. In significantly ( $p < 0.0001$ ) more cycles in the 23-day regimen group, participants reported withdrawal bleeding periods that lasted only 1–4 days compared to the 21-day regimen group. For the majority of the treatment cycles, the median number of bleeding days in the 23-day regimen group was 4 days and in the 21-day regimen group 5 days.

Both preparations were well tolerated and showed a similar adverse events pattern. The discontinuation rate because of adverse events was low (23-day regimen, 6%; 21-day regimen, 4%). No serious vascular adverse events were reported. More than 75% of the women in both groups either lost more than 2 kg of weight or did not gain weight during the study. The treatment effect on blood pressure was negligible. There were no appreciable changes in mean laboratory values over the course of the study. © 2001 Elsevier Science Inc. All rights reserved.

**Keywords:** Oral contraceptives; Ethinyl estradiol; Gestodene; Cycle control; 23-day regimen

### 1. Introduction

In the past few years, extensive clinical data has been collected on low-dose oral contraceptives (OCs) containing 20  $\mu\text{g}$  ethinyl estradiol, particularly in combination with gestodene [1–5]. Despite some initial doubts about reducing the estrogen dose to this level, it has become an established

fact that 20  $\mu\text{g}$  ethinyl estradiol, in combination with gestodene, desogestrel, or levonorgestrel provides effective contraceptive protection [1–3,6,7]. Although the cycle control efficacy of these preparations has been questioned, clinical experience suggests that cycle control, particularly after an initial phase of adaptation, is generally acceptable. Nevertheless, innovations that optimize the cycle control of these low-dose preparations most likely will increase compliance and benefit users.

Modification of the dosage regimen could be one approach to reduce the frequency of intracyclic bleeding. In

\* Corresponding author. Tel.: +49-30-4681-7864; fax: +49-30-4681-8191.

E-mail address: jan.endrikat@schering.de (J. Endrikat).

the present study, we investigated the effect of prolongation of treatment from 21 to 23 days, while shortening the hormone-free interval from 7 to 5 days, on the length of withdrawal bleeding periods and on intracyclic bleeding rates. Moreover, we examined whether the reduction in hormone concentration fluctuations with this new regimen led to improvement in the general tolerability of the preparation. As shown in a previous study, the prolongation of the intake phase significantly increased the degree of suppression of ovarian follicle development and resulted in lower  $17\beta$ -estradiol serum levels.

## 2. Materials and methods

In the present study, we compared contraceptive efficacy, cycle control, and tolerability of a 23-day versus a 21-day OC regimen containing 20  $\mu\text{g}$  ethinyl estradiol/75  $\mu\text{g}$  gestodene. The study was conducted as a phase III, multicenter, double-blind, randomized, study in three European countries over a period of seven treatment cycles. This prospective study was carried out from November 1994 to April 1998 at 32 centers in Denmark, the Netherlands, and Germany. The study protocol was reviewed and approved by all appropriate ethics committees.

The investigators recruited a total of 832 healthy 18–35 year old participants to the study, who requested contraception for at least 7 months. A total of 806 participants (4878 treatment cycles) provided data for the efficacy analysis. New OC users and participants who wanted to change their OC regimen (switchers) were included in the study. The switchers had to observe at least one OC-free wash-out cycle prior to intake of study medication. Other exclusion criteria were the established OC intake contraindications, the use of parenteral depot-contraceptives during the 6 months before the study began, specified concurrent diseases, vaginal bleeding of unknown origin, and a history of migraine accompanying menstruation. All participants gave informed consent prior to their participation in the trial.

Starting on the first day of withdrawal bleeding period, the participants received either 23 or 21 tablets of 20  $\mu\text{g}$  ethinyl estradiol/75  $\mu\text{g}$  gestodene followed either by 5 or by 7 placebos. The study medications were supplied in calendar packs. If a participant missed the scheduled intake time, she was instructed to take the tablet until up to 12 h after the scheduled time. All deviations from the specified intake regimen were recorded daily in a diary designed for this purpose.

Before treatment began, the participants underwent a thorough medical and gynecological examination including cervical cytology by the Papanicolaou method and exclusion of pregnancy. Also in the Netherlands and Germany, routine laboratory examinations (liver enzymes, hematologic parameters, lipids, creatinine, bilirubin, alkaline phosphatase, total protein and electrolytes) were carried out by

vention and Diagnosis, Leiden; Germany: LKF, Laboratorium für Klinische Forschung, Lise-Meitner-Str. Kiel, Germany).

The participants were questioned about their cycle length and withdrawal bleeding patterns before being admitted to the study. Cycle control parameters, blood pressure, and body weight were recorded during the pretreatment cycle, treatment Cycles 3 and 7, and in the follow-up phase of the study. In the follow-up phase the participants were re-questioned about their general health during the treatment phase. Medical and gynecological examinations, including a Papanicolaou smear and routine laboratory examinations, were repeated at the end of the study.

Bleeding patterns were documented by the participants throughout the study on a daily basis in individual diaries. If withdrawal bleeding failed to occur, a human chorionic gonadotropin (HCG) test was performed to exclude pregnancy before the treatment was continued. Pregnancies and all conditions during the preceding treatment cycles that might have impaired the reliability of contraceptive protection were noted.

Intracyclic bleeding during treatment Cycles 2–7 was defined as all vaginal bleeding occurring between cycle day 4 through cycle day 21 for 21-day regimen and between cycle day 6 through cycle day 23 for 23-day regimen. Therefore, the intracyclic bleeding assessment period was 17 days for both regimens. Intracyclic bleeding was assessed as either “spotting,” bleeding not requiring sanitary protection, or “normal/excessive breakthrough bleeding,” bleeding requiring sanitary protection. The incidence of spotting and normal/excessive breakthrough bleeding and the occurrence of amenorrhea (missed withdrawal bleeding) and dysmenorrhea were included in the efficacy analyses.

All unfavorable changes in the participant's condition were defined as adverse events and were recorded. The protocol included a list of adverse events that required study withdrawal. These included pregnancy and any evidence for an increased thrombotic risk. Treatment compliance, including a record of missed tablets, was monitored on a menstruation chart and was assessed by the investigator at each of the planned study visits.

### 2.1. Statistical methods

Statistical analyses were performed on both the “intention-to-treat” (ITT) and the “valid case” (VC) populations. All randomized participants who took at least one dose of the study medication were included in all ITT population analyses. All of the data from volunteers who had a major protocol deviation were excluded from the VC population analyses.

The study primary target variable was the percent of participants who had at least one intracyclic bleeding episode from the 2nd to the 4th treatment cycle. The null hypothesis that the probability of the occurrence of at least

not less than that under the 21-day regimen during the 2nd, 3rd, and 4th pill-taking cycles was tested against its alternative that this probability under the 23-day regimen is less than that under the 21-day regimen. The null hypotheses was tested by using a Fisher's exact test at a significance level  $\alpha$  of 5%.

The Pearl Index was calculated as 1300 times the number of pregnancies divided by the number of cycles. All pregnancies were included in the calculation, regardless of user failure. However, the study Pearl Indexes calculated should be interpreted with caution because the precision of the indexes is limited due to the sample size of the study.

Also, an exploratory test comparing the length of withdrawal bleeding periods for Cycles 1–6 was performed for the two treatment groups. Cycle 7 was excluded because start of poststudy medication prohibited correct determination of length of the last withdrawal bleeding period. For each participant the number of short withdrawal bleeding periods, i.e. those lasting 1–4 days, was determined. Because not all participants provided data for the same number of cycles, the percentage of cycles with short withdrawal bleeding periods was computed per participant. The null hypothesis that median of this variable is equal for the two regimens was tested against its alternative of inequality with a two-sided Wilcoxon rank sum test at a significance level  $\alpha$  of 5%.

### 3. Results

Of the 832 participants randomized, 806 received medication as either a 23-day regimen ( $n = 395$ ; 2533 cycles) or a 21-day regimen ( $n = 411$ ; 2670 cycles). Major protocol violations, such as not meeting inclusion criteria (age  $>40$  years, obesity, excessive smoking, incorrect wash-out cycle for women switching from another OC), prohibited co-medication intake or violation of the treatment schedule (irregular pill-intake) were recorded in 103 volunteers. The data from these participants were only included in the ITT analysis. The data from 703 participants were included in the VC analyses [23-day regimen,  $n = 342$  (2362 cycles); 21-day regime,  $n = 361$  (2516 cycles)]. The demographic characteristics of both treatment groups were well matched at baseline, as shown in Table 1.

#### 3.1. Contraceptive efficacy

In each treatment group, one participant became pregnant during the study medication phase. In the 23-day regimen group, one participant experienced vaginal bleeding and was hospitalized for evacuation. Fetal material was not found, but an "Arias-Stella-Phenomenon," a histomorphological correlate typical either for an abortion or ectopic pregnancy, was described by the consulting pathologist. The participant's ensuing  $\beta$ -HCG blood tests declined rapidly from 40 to 0 IU/L. The investigator evaluated the incident as

Table 1  
Demographic characteristics at baseline

	23-day regimen ( $n = 395$ )	21-day regimen ( $n = 411$ )
Mean age (years)	25.2	25.2
[range]	[18–35]	[15–35]
Mean weight (kg)	64.0	64.5
[range]	[42–95]	[42–94]
Mean height (cm)	168.6	168.6
[range]	[149–195]	[152–186]
Smoking prevalence (% of subjects)	23.5	28.0
Prior OC use (% of subjects)	47.3	49.9
Subjects with regular cycles (%)	95.7	95.6
Median menstrual duration (days)	5	5
[range]	[1–11]	[2–10]

a spontaneously reabsorbed ectopic pregnancy. Also, a participant in the 21-day regimen group became pregnant during the second treatment cycle. Both pregnancies were assessed as method failures. Based on this data, study Pearl Indices of 0.5 were calculated for each treatment.

#### 3.2. Cycle control

Cycle control was good in both treatment groups. The cumulative percent of participants with any intracyclic bleeding episodes (spotting and/or breakthrough bleeding) from Cycle 2 to 4 (primary target) was 36.0% for the 23-day regimen and 37.1% for the 21-day regimen (Fig. 1). This difference (1.1%) was not significant ( $p = 0.4055$ ). The cumulative intracyclic bleeding rates for Cycles 2–7 and 1–7 were similar (Fig. 1).

As the trial progressed, the percent of 23-day regimen participants with any intracyclic bleeding decreased from 42.4% in Cycle 1 to 14% in Cycle 7, and for the 21-day regimen participants from 44.6% to 17.3%, respectively (Fig. 2). Overall, in 21.9% of the 23-day regimen cycles and in 22.7% of the 21-day regimen cycles, intracyclic bleeding was reported.

The results for spotting were very similar to those for any intracyclic bleeding: 21.3% (23-day regimen) and 22% (21-day regimen) of all cycles were affected. In about 6% of all treated cycles in both groups, normal/excessive intracyclic bleeding was recorded.

In each treatment cycle, a greater number of 23-day regimen participants had shorter withdrawal bleeding periods, lasting 1–4 days, than in the 21-day regimen group. At baseline (pretreatment cycle), 42% of the participants in both treatment groups reported withdrawal bleeding periods that lasted between 1 and 4 days. The percent of participants with withdrawal bleeding periods that lasted 1–4 days increased to 60% in the 23-day regimen group during treatment (Fig. 3). Short withdrawal bleeding periods (1–4 days) were reported in 55.1% cycles treated with the 23-day regimen and in 43.2% of the cycles in the 21-day regimen. An exploratory analysis of the data showed that this differ-

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.